{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-12T17:36:05.128851+00:00","company":{"ticker":"NBIX","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC"},"pagination":{"limit":100,"returned":32,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Soleno Therapeutics, Inc.","detail":"merger","count":1,"first_seen":"2026-04-06T23:59:59+00:00","last_seen":"2026-04-06T23:59:59+00:00","evidence_fact_ids":[25449]},{"display_name":"Voyager Therapeutics, Inc.","detail":"collaboration","count":1,"first_seen":"2023-01-09T23:59:59+00:00","last_seen":"2023-01-09T23:59:59+00:00","evidence_fact_ids":[187228]}],"lender":[{"display_name":"JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto","detail":"revolving_credit","count":1,"first_seen":"2026-05-18T13:04:56+00:00","last_seen":"2026-05-18T13:04:56+00:00","evidence_fact_ids":[55046]}],"ma_counterparty":[{"display_name":"Soleno Therapeutics, Inc.","detail":"acquisition","count":1,"first_seen":"2026-05-18T13:04:56+00:00","last_seen":"2026-05-18T13:04:56+00:00","evidence_fact_ids":[54017]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"08b00492ea10d1e025e2e44570d58d1a6a303645","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-28T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-27","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"67,957","votes_against":"6,170,483","votes_for":"83,880,185","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-27 meeting.","evidence_excerpt":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non-votes 83,880,185 6,170,483 67,957 — The appointment of Ernst & Young LLP was ratified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-26-000029","anchor_url":"https://secwatch.observer/filing/0000914475-26-000029#claim-08b00492ea10d1e025e2e44570d58d1a6a303645","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fb80f94ec9a84ce7a51b138eb02025ff30bd9617","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-28T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-27","outcome":"passed","proposal_text":"Approval of the Amended 2025 Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,352,345","subject":null,"votes_abstain":"65,732","votes_against":"5,568,926","votes_for":"79,131,622","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Approval of the Amended 2025 Plan at the 2026-05-27 meeting.","evidence_excerpt":"Approval of the Amended 2025 Plan. Votes For Votes Against Abstentions Broker Non-votes 79,131,622 5,568,926 65,732 5,352,345 The Amended 2025 Plan was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-26-000029","anchor_url":"https://secwatch.observer/filing/0000914475-26-000029#claim-fb80f94ec9a84ce7a51b138eb02025ff30bd9617","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"828e26c96a2bdef2f44398f178debf05f78d8760","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-28T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-27","outcome":"passed","proposal_text":"An advisory vote on the compensation paid to the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,352,345","subject":null,"votes_abstain":"103,231","votes_against":"5,669,155","votes_for":"78,993,894","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved An advisory vote on the compensation paid to the Company's named executive officers at the 2026-05-27 meeting.","evidence_excerpt":"An advisory vote on the compensation paid to the Company's named executive officers. Votes For Votes Against Abstentions Broker Non-votes 78,993,894 5,669,155 103,231 5,352,345 The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-26-000029","anchor_url":"https://secwatch.observer/filing/0000914475-26-000029#claim-828e26c96a2bdef2f44398f178debf05f78d8760","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ddd39032f4e6b089b7a96545c6bc7eb209ae02e5","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-28T20:01:33+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-27","outcome":"passed","proposal_text":"Election of three Class III Directors for a term of three years expiring at the 2029 Annual Meeting of Stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"5,352,345","subject":"Kevin C. Gorman, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"76,228,063","votes_withheld":"8,538,217"},{"broker_non_votes":"5,352,345","subject":"Gary A. Lyons","votes_abstain":null,"votes_against":null,"votes_for":"75,278,705","votes_withheld":"9,487,575"},{"broker_non_votes":"5,352,345","subject":"Johanna Mercier","votes_abstain":null,"votes_against":null,"votes_for":"74,671,942","votes_withheld":"10,094,338"}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Election of three Class III Directors for a term of three years expiring at the 2029 Annual Meeting of Stockholders at the 2026-05-27 meeting.","evidence_excerpt":"Election of three Class III Directors for a term of three years expiring at the 2029 Annual Meeting of Stockholders. Votes For Votes Withheld Broker Non-votes Kevin C. Gorman, Ph.D. 76,228,063 8,538,217 5,352,345 Gary A. Lyons 75,278,705 9,487,575 5,352,345 Johanna Mercier 74,671,942 10,094,338 5,352,345 The three nominees for Class III Director were elected.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-26-000029","anchor_url":"https://secwatch.observer/filing/0000914475-26-000029#claim-ddd39032f4e6b089b7a96545c6bc7eb209ae02e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000029/0000914475-26-000029-index.htm"},{"fact_type":"debt_financing","fact_key":"709977ce071e9f877b6dc826c190741c139178d2","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-18T13:04:56+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto","effective_date":"2026-05-14","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu","item_codes_triggered":["2.03"],"maturity_text":"fifth anniversary of the Closing Date","principal_text":"$1.0 billion"},"claim":"NEUROCRINE BIOSCIENCES INC incurred revolving credit of $1.0 billion with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders party thereto at Term SOFR plus a margin of 1.125% to 1.75% per annum, or alternate base rate plu maturing fifth anniversary of the Closing Date.","evidence_excerpt":"On May 14, 2026 (the “ Closing Date ”), the Company entered into a credit agreement (the “ Credit Agreement ”) with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (in such capacities, the “ Agent ”), and the lenders party thereto. The Credit Agreement provides for a five-year, $1.0 billion senior secured revolving credit facility (the “ Revolving Credit Facility ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-228013","anchor_url":"https://secwatch.observer/filing/0001193125-26-228013#claim-709977ce071e9f877b6dc826c190741c139178d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm"},{"fact_type":"ma_transaction","fact_key":"db7ac0d4a7eeff6071334b4f7e3c0990f65ca965","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-18T13:04:56+00:00","payload":{"action":"acquisition","closing_date":"2026-05-18","consideration_text":"$53.00 per Soleno Share","counterparty":"Soleno Therapeutics, Inc.","effective_date":"2026-05-18","item_codes_triggered":["2.01"]},"claim":"NEUROCRINE BIOSCIENCES INC completed an acquisition involving Soleno Therapeutics, Inc. for $53.00 per Soleno Share (closed 2026-05-18).","evidence_excerpt":"through Purchaser, commenced a tender offer to purchase all the outstanding shares of Soleno’s common stock, par value $0.001 per share (the “ Soleno Shares ”), at a price of $53.00 per Soleno Share (the “ Offer Price ”), in cash, without interest and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-228013","anchor_url":"https://secwatch.observer/filing/0001193125-26-228013#claim-db7ac0d4a7eeff6071334b4f7e3c0990f65ca965","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526228013/0001193125-26-228013-index.htm"},{"fact_type":"earnings_release","fact_key":"4b9fbeddc1d92f93c69adfed93426232156f90a9","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"1.91 dollars per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"197.9 million dollars","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"814.5 million dollars"},"claim":"NEUROCRINE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue 814.5 million dollars, net income 197.9 million dollars, EPS 1.91 dollars per share. Guidance reaffirmed.","evidence_excerpt":"Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000914475-26-000025","anchor_url":"https://secwatch.observer/filing/0000914475-26-000025#claim-4b9fbeddc1d92f93c69adfed93426232156f90a9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm"},{"fact_type":"material_agreement","fact_key":"d384db782216276093cc91c172feb4a43da357d3","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-04-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"Soleno Therapeutics, Inc.","effective_date":"2026-04-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"NEUROCRINE BIOSCIENCES INC entered into Merger Agreement with Soleno Therapeutics, Inc. (effective 2026-04-05).","evidence_excerpt":"On April 5, 2026, Neurocrine Biosciences, Inc., a Delaware corporation (“ Neurocrine ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine (“ Purchaser ”), and Soleno Therapeutics, Inc., a Delaware corporation (“ Soleno ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-142904","anchor_url":"https://secwatch.observer/filing/0001193125-26-142904#claim-d384db782216276093cc91c172feb4a43da357d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm"},{"fact_type":"executive_change","fact_key":"d6f2976a79","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-05-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-02","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-25-000139","anchor_url":"https://secwatch.observer/filing/0000914475-25-000139#claim-d6f2976a79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm"},{"fact_type":"executive_change","fact_key":"4a5933426c","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-05-30T23:59:59+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-06-02","interim":false,"role":"Strategic Advisor to the CEO","role_category":"other","successor_name":"Sanjay Keswani","successor_named":true},"claim":"Eiry W. Roberts changed role as Strategic Advisor to the CEO at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-25-000139","anchor_url":"https://secwatch.observer/filing/0000914475-25-000139#claim-4a5933426c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000139/0000914475-25-000139-index.htm"},{"fact_type":"executive_change","fact_key":"afdd83c9fb","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-04-04T23:59:59+00:00","payload":{"action":"succeeded","action_category":"departure","departure_tone":"retirement","effective_date":"2025-06-02","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":"Sanjay Keswani","successor_named":true},"claim":"Eiry W. Roberts departed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-25-000081","anchor_url":"https://secwatch.observer/filing/0000914475-25-000081#claim-afdd83c9fb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm"},{"fact_type":"executive_change","fact_key":"de94bd0efc","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-04-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-02","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-25-000081","anchor_url":"https://secwatch.observer/filing/0000914475-25-000081#claim-de94bd0efc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000081/0000914475-25-000081-index.htm"},{"fact_type":"executive_change","fact_key":"2496aa104d","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-10-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-11","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000914475-24-000206","anchor_url":"https://secwatch.observer/filing/0000914475-24-000206#claim-2496aa104d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000206/0000914475-24-000206-index.htm"},{"fact_type":"executive_change","fact_key":"63c7ce5383","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-11","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Kyle Gano was appointed as Class II Director at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-148107","anchor_url":"https://secwatch.observer/filing/0001193125-24-148107#claim-63c7ce5383","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm"},{"fact_type":"executive_change","fact_key":"c3ecb2d928","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-11","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-148107","anchor_url":"https://secwatch.observer/filing/0001193125-24-148107#claim-c3ecb2d928","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm"},{"fact_type":"executive_change","fact_key":"10f4c05fc9","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-10-11","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Kyle Gano","successor_named":true},"claim":"Kevin C. Gorman retired as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-148107","anchor_url":"https://secwatch.observer/filing/0001193125-24-148107#claim-10f4c05fc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm"},{"fact_type":"earnings_release","fact_key":"45088c1280115973dfb812295130ce4094d72e8c","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-01T23:59:59+00:00","payload":{"eps_text":"$0.42","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$43.4 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-01","result_type":"reported_results","revenue_text":"$515.3 million"},"claim":"NEUROCRINE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $515.3 million, net income $43.4 million, EPS $0.42. Guidance reaffirmed.","evidence_excerpt":"Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-24-000116","anchor_url":"https://secwatch.observer/filing/0000914475-24-000116#claim-45088c1280115973dfb812295130ce4094d72e8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm"},{"fact_type":"earnings_release","fact_key":"79beccdada401352fa3ddd164308ebcfff172322","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-02-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-02-07","result_type":"reported_results","revenue_text":null},"claim":"NEUROCRINE BIOSCIENCES INC updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 7, 2024, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-24-000033","anchor_url":"https://secwatch.observer/filing/0000914475-24-000033#claim-79beccdada401352fa3ddd164308ebcfff172322","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000033/0000914475-24-000033-index.htm"},{"fact_type":"earnings_release","fact_key":"18d05c219bbb7df06cddc220e46064ea28ca7580","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-10-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-10-31","result_type":"reported_results","revenue_text":null},"claim":"NEUROCRINE BIOSCIENCES INC updated its the third quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On October 31, 2023, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-23-000072","anchor_url":"https://secwatch.observer/filing/0000914475-23-000072#claim-18d05c219bbb7df06cddc220e46064ea28ca7580","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm"},{"fact_type":"executive_change","fact_key":"1312e730b8","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-07-13T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Eiry W. Roberts retired as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"On July 10, 2023, Eiry W. Roberts, M.D., notified Neurocrine Biosciences, Inc. (the “Company”) of her decision to retire in 2025 from her position as Chief Medical Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-23-000049","anchor_url":"https://secwatch.observer/filing/0000914475-23-000049#claim-1312e730b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000049/0000914475-23-000049-index.htm"},{"fact_type":"governance_change","fact_key":"2928d60931ff59c289ad101473e947ed5af98579","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-07-12T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-07-11","item_codes_triggered":["5.03"],"summary_text":"Amended Section 3.2 of Bylaws to increase board size from nine to ten members."},"claim":"NEUROCRINE BIOSCIENCES INC: Amended Section 3.2 of Bylaws to increase board size from nine to ten members (effective 2023-07-11).","evidence_excerpt":"On July 11, 2023, the Board amended Section 3.2 of Neurocrine’s Bylaws, as amended and restated (the “Bylaws”), to provide that the Board shall consist of ten members.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-23-000047","anchor_url":"https://secwatch.observer/filing/0000914475-23-000047#claim-2928d60931ff59c289ad101473e947ed5af98579","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/0000914475-23-000047-index.htm"},{"fact_type":"executive_change","fact_key":"ff6e377709","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-07-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-07-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christine A. Poon was appointed as Director at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"On July 11, 2023, the Board of Directors (the “Board”) of Neurocrine Biosciences, Inc., a Delaware corporation (“Neurocrine”), upon the recommendation of its Nominating / Corporate Governance Committee, appointed Christine A. Poon as a member of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-23-000047","anchor_url":"https://secwatch.observer/filing/0000914475-23-000047#claim-ff6e377709","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000047/0000914475-23-000047-index.htm"},{"fact_type":"shareholder_vote","fact_key":"50ef73aa05b72c77276a60a3c65512e3242bc010","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"49,588","votes_against":"6,163,365","votes_for":"80,314,052","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-17 meeting.","evidence_excerpt":"Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. Shares Voted: For 80,314,052 Against 6,163,365 Abstain 49,588 Percent of Voted: For 92.82 % Against 7.12 % The appointment of Ernst & Young LLP was ratified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-149520","anchor_url":"https://secwatch.observer/filing/0001193125-23-149520#claim-50ef73aa05b72c77276a60a3c65512e3242bc010","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4f8f65b62cab0f9f3329f8c09a44cb1dba803be6","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Approval of the Amended 2020 Plan.","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,004,423","subject":null,"votes_abstain":"72,654","votes_against":"12,198,955","votes_for":"69,250,973","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Approval of the Amended 2020 Plan. at the 2023-05-17 meeting.","evidence_excerpt":"Approval of the Amended 2020 Plan. Shares Voted: For 69,250,973 Against 12,198,955 Abstain 72,654 Percent of Voted: For 84.95 % Against 14.96 % There were 5,004,423 broker non-votes for this proposal. The Amended 2020 Plan was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-149520","anchor_url":"https://secwatch.observer/filing/0001193125-23-149520#claim-4f8f65b62cab0f9f3329f8c09a44cb1dba803be6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm"},{"fact_type":"shareholder_vote","fact_key":"82d9d91c192f83740dca2aa05dfef9510dd3226b","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Advisory vote on the frequency of advisory voting on the compensation paid to the Company's named executive officers.","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"5,004,423","subject":null,"votes_abstain":"56,084","votes_against":"23,501","votes_for":"80,717,040","votes_withheld":"725,957"}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Advisory vote on the frequency of advisory voting on the compensation paid to the Company's named executive officers. at the 2023-05-17 meeting.","evidence_excerpt":"An advisory vote on the frequency of advisory voting on the compensation paid to the Company's named executive officers. Shares Voted: 1 Year 80,717,040 2 Years 23,501 3 Years 725,957 Abstain 56,084 Percent of Voted: 1 Year 99.01 % 2 Years 0.03 % 3 Years 0.89 % There were 5,004,423 broker non-votes for this proposal. In light of this result, the Company will hold future say on pay votes on an annual basis until the next advisory vote on the frequency of say on pay votes occurs.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-149520","anchor_url":"https://secwatch.observer/filing/0001193125-23-149520#claim-82d9d91c192f83740dca2aa05dfef9510dd3226b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d1db3d451d6cbdd98954b1d3e465246f77ac6c3e","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Advisory vote on the compensation paid to the Company's named executive officers.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,004,423","subject":null,"votes_abstain":"61,094","votes_against":"5,557,583","votes_for":"75,903,905","votes_withheld":null}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Advisory vote on the compensation paid to the Company's named executive officers. at the 2023-05-17 meeting.","evidence_excerpt":"An advisory vote on the compensation paid to the Company's named executive officers. Shares Voted: For 75,903,905 Against 5,557,583 Abstain 61,094 Percent of Voted: For 93.11 % Against 6.82 % There were 5,004,423 broker non-votes for this proposal. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-149520","anchor_url":"https://secwatch.observer/filing/0001193125-23-149520#claim-d1db3d451d6cbdd98954b1d3e465246f77ac6c3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a34c90acac490815fdcabf34109874ab70b5c15d","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-05-19T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-17","outcome":"passed","proposal_text":"Election of three Class III Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders.","proposal_type":"director_election","results":[{"broker_non_votes":"5,004,423","subject":"Kevin C. Gorman, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"79,212,382","votes_withheld":"2,310,200"},{"broker_non_votes":"5,004,423","subject":"Gary A. Lyons","votes_abstain":null,"votes_against":null,"votes_for":"67,873,034","votes_withheld":"13,649,548"},{"broker_non_votes":"5,004,423","subject":"Johanna Mercier","votes_abstain":null,"votes_against":null,"votes_for":"73,442,103","votes_withheld":"8,080,479"}]},"claim":"NEUROCRINE BIOSCIENCES INC shareholders approved Election of three Class III Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders. at the 2023-05-17 meeting.","evidence_excerpt":"Election of three Class III Directors for a term of three years expiring at the 2026 Annual Meeting of Stockholders. Kevin C. Gorman, Ph.D. For 79,212,382 Withheld 2,310,200 Gary A. Lyons For 67,873,034 Withheld 13,649,548 Johanna Mercier For 73,442,103 Withheld 8,080,479 There were 5,004,423 broker non-votes for this proposal. The three nominees for Class III Director were elected.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-149520","anchor_url":"https://secwatch.observer/filing/0001193125-23-149520#claim-a34c90acac490815fdcabf34109874ab70b5c15d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm"},{"fact_type":"governance_change","fact_key":"8e263b4150c134c31692152c886bc56c6b8fb6d2","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-02-10T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-02-09","item_codes_triggered":["5.03"],"summary_text":"Amended and restated Bylaws to implement a proxy access provision and update procedural requirements for stockholder nominations and proposals."},"claim":"NEUROCRINE BIOSCIENCES INC: Amended and restated Bylaws to implement a proxy access provision and update procedural requirements for stockholder nominations and proposals (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, the board of directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Restated Bylaws”) which became effective immediately upon adoption by the Board.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-23-000013","anchor_url":"https://secwatch.observer/filing/0000914475-23-000013#claim-8e263b4150c134c31692152c886bc56c6b8fb6d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/0000914475-23-000013-index.htm"},{"fact_type":"earnings_release","fact_key":"586cc380687cb74f8c5da6b22767247215521a14","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-02-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 31, 2022","report_date":"2023-02-06","result_type":"reported_results","revenue_text":null},"claim":"NEUROCRINE BIOSCIENCES INC reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On February 6, 2023, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-23-000005","anchor_url":"https://secwatch.observer/filing/0000914475-23-000005#claim-586cc380687cb74f8c5da6b22767247215521a14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000005/0000914475-23-000005-index.htm"},{"fact_type":"material_agreement","fact_key":"9158ac9dead4f84edd5165581822286255a69760","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-01-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Collaboration and License Agreement","agreement_type":"collaboration","counterparty":"Voyager Therapeutics, Inc.","effective_date":"2023-01-08","item_codes_triggered":["1.01"],"value_text":"approximately $136.0 million"},"claim":"NEUROCRINE BIOSCIENCES INC entered into Collaboration and License Agreement with Voyager Therapeutics, Inc. valued at approximately $136.0 million (effective 2023-01-08).","evidence_excerpt":"On January 8, 2023 (the “Agreement Date”), Neurocrine Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Voyager Therapeutics, Inc. (“Voyager”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000914475-23-000003","anchor_url":"https://secwatch.observer/filing/0000914475-23-000003#claim-9158ac9dead4f84edd5165581822286255a69760","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000003/0000914475-23-000003-index.htm"},{"fact_type":"earnings_release","fact_key":"5b0a82789b0b8aaebffbe1aabc5f21b165d59f87","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-11-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Fiscal year 2022","report_date":"2022-11-01","result_type":"guidance_update","revenue_text":"INGREZZA Net Product Sales 1 $ 1,400 $ 1,425"},"claim":"NEUROCRINE BIOSCIENCES INC reported Fiscal year 2022 results: revenue INGREZZA Net Product Sales 1 $ 1,400 $ 1,425. Guidance raised.","evidence_excerpt":"Updated 2022 INGREZZA Sales and Reaffirmed Operating Expense Guidance: Range (in millions) Low High INGREZZA Net Product Sales 1 $ 1,400 $ 1,425 GAAP R&D expense 2 $ 415 $ 450 Non-GAAP R&D expense 3 $ 360 $ 395 GAAP SG&A expense $ 720 $ 735 Non-GAAP SG&A expense 3 $ 605 $ 620 1.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-22-000055","anchor_url":"https://secwatch.observer/filing/0000914475-22-000055#claim-5b0a82789b0b8aaebffbe1aabc5f21b165d59f87","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm"},{"fact_type":"earnings_release","fact_key":"23eb100f3d00160854cd3c2e8c41fe8d00a750c9","cik":914475,"ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-11-01T23:59:59+00:00","payload":{"eps_text":"GAAP earnings per share – diluted $ 0.69","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"GAAP net income $ 68.5","period_text":"Third quarter ended September 30, 2022","report_date":"2022-11-01","result_type":"reported_results","revenue_text":"Total revenues $ 387.9"},"claim":"NEUROCRINE BIOSCIENCES INC reported Third quarter ended September 30, 2022 results: revenue Total revenues $ 387.9, net income GAAP net income $ 68.5, EPS GAAP earnings per share – diluted $ 0.69.","evidence_excerpt":"Total revenues $ 387.9 $ 296.0 $ 1,076.7 $ 821.5\nGAAP Research and Development (R&D) $ 107.7 $ 92.7 $ 345.8 $ 240.7\nNon-GAAP R&D $ 92.8 $ 80.7 $ 302.2 $ 204.5\nGAAP Selling, General and Administrative (SG&A) $ 186.3 $ 154.6 $ 569.8 $ 426.8\nNon-GAAP SG&A $ 158.1 $ 129.5 $ 483.8 $ 364.4\nGAAP net income $ 68.5 $ 22.5 $ 65.5 $ 96.9\nGAAP earnings per share – diluted $ 0.69 $ 0.23 $ 0.67 $ 0.99","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000914475-22-000055","anchor_url":"https://secwatch.observer/filing/0000914475-22-000055#claim-23eb100f3d00160854cd3c2e8c41fe8d00a750c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm"}]}